Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.52 |
| ▸ | NPY1R | P25929 | 9/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.52 |
| ▸ | NPY2R | P49146 | 5/20 | 0.52 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13448837 | 1.00 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29531971 | 0.99 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30903436 | 0.99 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29658146 | 0.95 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL13449160 | 0.94 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29540421 | 0.93 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29461973 | 0.93 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30900195 | 0.93 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30900117 | 0.93 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL31074830 | 0.92 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695258-A1 | BENZOPORPHYRIN ANALOGS, CONJUGATES, AND METHODS OF USE THEREOF | Nira Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | US | claimed |
| WO-2025120085-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | WO | claimed |
| WO-2025106566-A2 | FLUOROGENIC BIFUNCTIONAL PROBE OF PROTEASE ACTIVITY | Life Technologies Corporation (US) | 2025-05-22 | — | — | WO | claimed |
| WO-2024216150-A1 | BENZOPORPHYRIN ANALOGS, CONJUGATES, AND METHODS OF USE THEREOF | NIRA BIOSCIENCES, INC. (US) | 2024-10-17 | — | — | WO | claimed |
| EP-4695258-A1 | BENZOPORPHYRIN ANALOGS, CONJUGATES, AND METHODS OF USE THEREOF | Nira Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250302981-A1 | NOVEL USE OF ANTICANCER AGENT PRODRUG CONJUGATE | UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION (KR) | 2025-10-02 | — | — | US | disclosed |
| US-20250281627-A1 | CANCER-TARGETING PEPTIDE, PRODRUG NANOPARTICLES COMPRISING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR CANCER PREVENTION OR TREATMENT | NOXPHARM CO., LTD. (KR) | 2025-09-11 | — | — | US | disclosed |
| WO-2025135352-A1 | INTESTINAL MACROPHAGE-TARGETING PRODRUG NANOASSEMBLY FOR TREATING INFLAMMATORY BOWEL DISEASE | 한국과학기술연구원 | 2025-06-26 | — | — | WO | disclosed |
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | US | disclosed |
| WO-2025120085-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025106566-A2 | FLUOROGENIC BIFUNCTIONAL PROBE OF PROTEASE ACTIVITY | Life Technologies Corporation (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2024216150-A1 | BENZOPORPHYRIN ANALOGS, CONJUGATES, AND METHODS OF USE THEREOF | NIRA BIOSCIENCES, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024111844-A1 | CANCER-TARGETING PEPTIDE, PRODRUG NANOPARTICLES COMPRISING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR CANCER PREVENTION OR TREATMENT | 이화여자대학교 산학협력단 | 2024-05-30 | — | — | WO | disclosed |
| WO-2023237060-A1 | AMPHIPHILIC BLOCK POLYMER, CHEMORADIOTHERAPY NANO SENSITIZER, AND METHOD FOR PREPARING SAME | 北京化工大学 | 2023-12-14 | — | — | WO | disclosed |
| US-20230173083-A1 | ALBUMIN-BINDING PRODRUG FOR PREVENTING OR TREATING CANCER AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | BCR, TBCD, TBC1D5 | NPY4R 4623/4885NPY1R 4687/4885NPY5R 4476/4885 |
| US-20250302981-A1 | NOVEL USE OF ANTICANCER AGENT PRODRUG CONJUGATE | KRAS, TP53, NRAS | NPY4R 4845/4885NPY1R 4861/4885NPY5R 4862/4885 |
| US-20230173083-A1 | ALBUMIN-BINDING PRODRUG FOR PREVENTING OR TREATING CANCER AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | ALB, TTR, TP53 | NPY4R 4613/4885NPY1R 4436/4885NPY5R 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.